Oxford BioMedica Plc has entered into a research and development collaboration with the Mayo Clinic in the US to develop a gene therapy for the treatment of chronic glaucoma. It is the company’s second partnership in the area of eye disease. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
